As the affinity of cetuximab for EGFR is nearly 5 to 10 times of the endogenous ligands, it can block endogenous ligand binding, which reduces EGFR-mediated signaling and leads to growth inhibition of tumor cells [13, 15]. This evidence concerns the gene EGFR and neoplasm.